Clinical Trial Update: A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing MORAb-202 to investigator's choice chemotherapy in women with platinum-resistant high-grade serous ovarian cancer and related gynecologi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• High-grade Serous Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Investigator's Choice Chemotherapy
• MORAb-202

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Neoplasms, Ovarian | Phase 2 | Status: COMPLETED | Results posted: 2025-07-03